

APPLICANTS: Kurtis et al.
U.S.S.N.: 10/008,340

In the claims:

Claim 1 (cancelled)

Claim 2 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 10, wherein the helminth is a hookworm, roundworm, pinworm or tapeworm.

Claim 3 (cancelled)

Claim 4 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 11, wherein the Schistosome species is *Schistosoma mansoni*, *Schistosoma japonicum*, or *Schistosoma hematobium*.

Claim 5 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 10, wherein the bioactive agent is a polypeptide.

Claim 6 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 5, wherein the polypeptide is a secreted polypeptide.

Claim 7 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 6, wherein the polypeptide is a post-translationally modified polypeptide.

Claim 8 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 7, wherein the post-translational modification is glycosylation.

APPLICANTS: Kurtis et al.
U.S.S.N.: 10/008,340

Claim 9 (currently amended): The ~~method of claim 1~~ sustained drug delivery device of claim 5, wherein the polypeptide is a cytokine, enzyme, hormone, or neurotransmitter.

Claim 10 (currently amended) A sustained drug delivery device comprising a stably transformed helminth male prepared according to ~~the~~ a method of claim 1 comprising introducing a nucleic acid encoding a bioactive agent into a female helminth; selecting a female stably transformed with said bioactive agent-encoding nucleic acid; crossing said stably transformed female to a non-transformed male helminth; and isolating a progeny male containing said stably transformed nucleic acid, thereby making a sustained drug delivery device.

Claim 11 (currently amended): The sustained drug delivery device of claim 10, wherein the helminth is a Schistosome species.

Claim 12 (original claim): A miracidia containing the sustained drug delivery device of claim 11.

Claim 13 (original claim): A snail containing the miracidia of claim 12.

Claim 14 (original claim): A cercaria comprising the sustained drug delivery device of claim 11.

Claim 15. (original claim): A pharmaceutical composition comprising the sustained delivery device of claim 11 and a pharmaceutically acceptable carrier.

APPLICANTS: Kurtis et al.
U.S.S.N.: 10/008,340

Claims 16-20 (cancelled)